Skip to main content


Connecting policy, reimbursement, clinical practice, and patient
need to help innovative glaucoma care reach the people who need
it


A medical innovation can be clinically sound, backed by evidence, and welcomed by
physicians, yet still remain out of reach for the patient who needs it. Between an ophthalmic
technology and the treatment room lies a complicated network of coding rules, coverage
policies, payer decisions, reimbursement mechanisms, provider practices, and institutional
considerations. Navigating that network requires more than technical knowledge. It requires
an understanding of how the different parts of the healthcare system interact.
That understanding has defined Elizabeth Kenny’s career.
As Head of Market Access at Iantrek, Kenny works at the intersection of reimbursement,
health economics, coding, payer relations, policy, and patient access. Her experience across
Allergan, Abbott, Eyenuk, and Glaukos has given her exposure to different organizations,
therapeutic environments, and healthcare models. Across those roles, one concern has
remained remarkably consistent: how to remove unnecessary barriers between patients and
appropriate care.
Her approach is grounded in practical experience rather than theory. She understands that a
reimbursement decision can have consequences far beyond an administrative department. A
coding issue can delay treatment. A restrictive policy can limit a surgeon’s options. A lack of
internal alignment can slow an otherwise promising launch.
For Kenny, market access is therefore not simply about securing reimbursement. It is about
understanding what stands between innovation and the patient, then doing the work required
to address it.
The Early Experiences That Shaped Her Perspective
Kenny’s connection to healthcare began through community health volunteer work. That
experience introduced her to health disparities and prompted a deeper interest in
understanding why access to care can differ so significantly among communities.
She pursued an MPH in Health Policy with a focus on global health, an academic path that
expanded her view of healthcare beyond individual treatment decisions.
She began to see how community, environment, culture, policy, and the commercial forces
within the United States healthcare system influence one another. Improving access, she
realized, requires an appreciation of the entire system rather than an isolated focus on
reimbursement.

That perspective became an important foundation for her professional life.
An access problem rarely has a single cause. Policy may influence reimbursement.
Reimbursement may influence provider behavior. Provider decisions may affect patient
choice. Commercial considerations can shape how technologies are introduced and
supported. Each element can alter the outcome.
Kenny carried that systems perspective with her as she moved deeper into reimbursement and
market access.
From Reimbursement Function to Career Purpose
Her professional journey took her through reimbursement, health economics, billing and
coding, payer relations, and market access at organizations including Allergan, Abbott,
Eyenuk, and Glaukos.
Each environment presented a different set of circumstances.
Some roles involved the dynamics of medical devices, others pharmaceuticals. Patient
therapies varied, organizational structures differed, and the stakeholders surrounding each
product were not always the same.
Yet the experiences gradually revealed a common challenge.
There was significant work still to be done to make access to care more straightforward.
Providers, manufacturers, payers, hospital systems, and private equity organizations can all
have different priorities. They operate within healthcare systems that continue to change,
while patient populations grow and reimbursement rules evolve.
Kenny found that complexity intellectually demanding, but also meaningful. The work had a
direct connection to patient care.
That combination changed the way she viewed reimbursement. What initially appeared to be
a functional discipline became a strategic field in which careful policy work, stakeholder
engagement, and problem solving could influence whether patients actually received
treatment.
It became the career she wanted to build.
When a Coding Question Becomes a Patient Access Issue
The significance of Kenny’s work becomes particularly clear when reimbursement policy and
clinical reality fall out of alignment.
She recently encountered a situation involving a new CPT code in which different agencies
held differing views about the appropriate coding language. The resulting uncertainty
prevented providers from using the code and billing for the procedure.

The consequences were tangible. Patients were waiting for care they could otherwise have
been receiving, while surgeons faced frustration over restrictions that could affect their ability
to choose how they treated their patients.
For Kenny, this was not simply a coding disagreement.
It was a patient access problem.
Her response was informed by both her reimbursement experience and her policy
background. Rather than allowing patients to remain caught between competing
interpretations, she focused on helping stakeholders move toward an agreed solution.
The episode illustrates an important part of her approach to market access. Policy is not
abstract when its interpretation determines whether a physician can provide a treatment.
Coding language is not merely administrative when its uncertainty delays patient care.
The practical consequences have to remain visible throughout the process.
An Achievement Measured by What Changed for Patients
Kenny is reluctant to describe her career through a single accomplishment. She sees
successful access work as the result of many people contributing their expertise toward the
same objective.
That perspective reflects the nature of market access itself. A reimbursement outcome can
involve physicians, policy specialists, commercial teams, manufacturers, payers, and other
stakeholders. No single person can create access in isolation.
One achievement from her time at Allergan nevertheless stands out.
Working alongside physician advocates, Kenny helped challenge an eye care policy
containing criteria that could have harmed patients if they were met. The effort moved to the
state level, where the policy was redrafted.
The result was expanded access to the eye care patients in that state needed.
For Kenny, that experience demonstrated what effective advocacy can accomplish when
professionals are willing to challenge a policy that does not align with patient needs.
Her definition of impact remains deliberately broad. It can mean influencing a state policy,
supporting a product launch, helping a medical office navigate reimbursement, or ensuring
that one claim is properly paid.
The scale may differ. The patient does not.

Leading From the Center of the Conversation
As Head of Market Access at Iantrek, Kenny occupies a role that requires her to connect
several disciplines that are essential to the success of an emerging ophthalmic technology.
Clinical value must be understood alongside economic evidence. Reimbursement policy has
to be considered alongside provider needs. Commercial objectives have to remain connected
to the experience of patients seeking treatment.
Kenny describes an effective market access leader as a connector.
Her responsibility is to help translate between functions so that important information does
not disappear as it moves from one part of the organization to another.
That requires a particular kind of culture.
People need to feel comfortable being transparent about what is working and what is not.
Clinical, health economics, sales, and market access teams need to recognize that they are
working toward one shared outcome.
Kenny’s role is to help create that environment while giving her team the knowledge and
confidence to advocate for patients and emerging technologies, whether the issue involves an
individual claim or a national policy discussion.
For her, collaboration is not separate from strategy. It is one of the conditions that allows
strategy to work.
Reimbursement Needs to Begin Before Commercialization
One of Kenny’s strongest recommendations to companies developing new ophthalmic
technologies is also one of the most practical.
Think about coding, coverage, and reimbursement from day one.
For companies developing glaucoma and other ophthalmic technologies, that means
understanding the realistic pathway for code development early in the process. Timing
matters as well, particularly the relationship between effective dates and existing policy
language.
Payer history deserves similar attention.
Companies need to understand how individual payers have historically documented coverage
decisions, what restrictions have appeared in previous policies, and which precedents could
influence the treatment of a new technology.

This preparation can help companies identify potential obstacles before they become launch
problems.
Yet Kenny does not view technical reimbursement preparation as the objective.
The objective is access.
Coding, coverage analysis, and payer research only become meaningful when they help
connect healthcare policy with the patient who needs treatment. A promising technology
should not reach the market only to spend unnecessary time waiting for the reimbursement
environment to catch up.
For Kenny, market access belongs in the development conversation from the beginning.
Protecting the Physician’s Choice
That principle becomes even more important in glaucoma, where patients can present with
different disease characteristics and different rates of progression.
Kenny believes reimbursement strategy should begin with the surgeon’s ability to choose the
procedure that best meets the needs of an individual patient.
When coding requirements, payer policies, clinical adoption, and regulatory considerations
are changing simultaneously, she focuses on three groups: the patient, the provider, and the
payer.
Education connects them.
Providers need to understand the reimbursement environment without losing sight of clinical
judgment. Payers need to understand the clinical reasoning behind treatment choices. Policy
work needs to reflect how physicians actually practice.
Kenny’s approach is not to treat every change as an isolated reimbursement problem. Instead,
she builds strategy around protecting appropriate provider choice.
That distinction matters.
The treatment that is simplest to code or easiest to cover is not necessarily the treatment that
is right for a particular patient. A well designed access strategy should allow clinical
judgment to remain part of the equation.
What a Difficult Experience Taught Her About Leadership
Not every professional lesson comes from a successful outcome.
One of Kenny’s most important leadership lessons came from experiencing what happens
when an organization lacks strong leadership and sound internal management.

Even a strong reimbursement strategy can stall when there is no clear direction, insufficient
organizational support, or a lack of accountability among leaders. When that happens, the
consequences are not limited to performance. Trust can deteriorate as well.
The experience changed the way Kenny thinks about leadership.
She came to appreciate that culture can determine whether strategy succeeds. People need
support, direction, and the confidence that their concerns will be heard.
That understanding now influences how she builds teams and approaches uncertainty.
A leader’s responsibility does not end with developing the strategy. The way people are
guided through difficult periods can determine whether that strategy has a chance to succeed.
Hiring for the Qualities That Cannot Be Taught
Kenny’s approach to team building follows the same practical philosophy.
She believes technical reimbursement skills can be developed. Coding, coverage, and payer
strategy can be taught through experience, training, and coaching.
Certain qualities are different.
Integrity, resilience, and genuine curiosity cannot simply be added through a training
program.
Kenny looks for people who naturally investigate problems, persist when the first solution
does not work, and maintain the patient’s interests when decisions become complicated.
That investigative instinct is particularly valuable in market access, where the answer to a
reimbursement question may not be immediately apparent. It can require research,
stakeholder conversations, policy analysis, and the willingness to keep looking when the first
answer proves insufficient.
Her experience training and coaching commercial teams has reinforced the importance of
developing both capability and judgment.
A strong market access team needs people who understand the technical details, but also
understand why those details matter.
Putting People First at Iantrek
At Iantrek, Kenny is working within a culture that emphasizes people, vulnerability, and
continuous improvement.
For her, translating those values into Market Access begins with something straightforward:
people first.

That means collaborating across functions, exercising patience, and taking the time to
understand what other teams are trying to accomplish rather than assuming that market access
priorities should always come first.
She also emphasizes positive intent in her interactions.
The reason is practical. Market access does not operate in isolation. Commercial teams,
clinical teams, health economics professionals, and other functions each bring different
responsibilities to the same company objective.
At Iantrek, that shared objective is particularly clear.
The company is advancing BIOS, or bio interventional ophthalmic surgery, approaches for
glaucoma patients. Kenny’s Market Access function has an important role in helping create
pathways for those approaches to reach the patients who need them.
When the patient remains the shared focus, collaboration becomes easier to understand.
Vulnerability becomes a willingness to acknowledge what needs improvement. Continuous
improvement becomes part of everyday work rather than a phrase reserved for corporate
presentations.
Preparing for the Next Phase of Ophthalmic Access
Kenny expects the ophthalmic market access environment to become more demanding over
the coming years.
A growing population of baby boomers requiring glaucoma surgery will increase demand for
treatment. At the same time, the healthcare system is becoming more complex, with a broader
mix of payer types and increasingly restrictive coverage policies.
As patient numbers grow, payers are likely to continue refining their coverage criteria.
Companies operating in ophthalmology will need to understand those changes and prepare
for them rather than simply responding after restrictions have already affected access.
Iantrek is approaching that environment by staying ahead of coding and policy developments.
The emphasis is on preparation rather than reaction.
For Kenny, that is essential because an increase in patients needing glaucoma surgery should
not automatically mean an increase in barriers to receiving it.
Commercial growth and patient access therefore have to be considered together.

A Career With One Consistent Measure of Success
There is a clear thread running through Elizabeth Kenny’s career.
The organizations have changed. The technologies have changed. The reimbursement
landscape has changed. Her responsibilities have expanded from reimbursement and coding
into broader market access leadership.
Her central concern has remained the same.
Can patients get the care they need?
Kenny hopes colleagues and industry peers will remember her as someone who kept trying to
answer that question, even when the path was complicated. She points to the work of
expanding policies, challenging restrictive criteria, investigating reimbursement barriers, and
looking for practical solutions across the organizations where she has worked.
It is a professional philosophy built less around individual recognition than sustained effort.
The work often happens away from the spotlight. It can involve policy language, payer
documentation, coding decisions, stakeholder conversations, internal alignment, and the
painstaking process of finding an acceptable path through a complicated system.
Yet those details can determine whether innovation becomes accessible care.
That is where Kenny has chosen to make her contribution.
At Iantrek, she continues to bring together policy knowledge, reimbursement experience,
commercial understanding, and a firm commitment to physician and patient needs. Her work
reflects an understanding that healthcare innovation only reaches its full value when the
systems surrounding it allow patients to benefit.
For Elizabeth Kenny, that means continuing to ask the difficult questions, continuing to
investigate the barriers, and continuing to look for ways forward.
The technologies will evolve. The policies will change. The reimbursement landscape will
continue to shift.
Her measure of the work remains much simpler: keep patients at the center, and keep
working to get them the care they need.

Leave a Reply

Your email address will not be published. Required fields are marked *